Urinary calcium excretion in treated and untreated essential hypertension.
A high prevalence of hypercalciuria has been reported in patients with essential hypertension. Nevertheless, the clinical and therapeutic implications of this finding have scarcely been studied. This study was designed to determine the prevalence of hypercalciuria in an unselected population with essential hypertension and to analyze the relationship between the urinary calcium and the clinical and therapeutic status of these patients. This article presents a prospective study of 112 patients with essential hypertension and 49 healthy normotensive control subjects. Urinary excretion rates of calcium, sodium, chloride, potassium, urinary calcium/creatinine index, the fractional excretion of sodium, potassium and uric acid, the creatinine clearance and serum values of creatinine, urea, uric acid, electrolytes, total proteins, parathormone (intact molecule), plasma renin activity, aldosterone, glucose, and insulin (fasting and after an oral glucose load) were performed in every patient and control subject. Untreated hypertensive patients had a higher prevalence of hypercalciuria (35% had a urinary calcium/creatinine ratio > 0.20 versus 20% of treated hypertensives and 2% of control subjects; P < 0.001). Patients on thiazide or beta-blocker monotherapy had lower urinary excretion rates of calcium and urate than patients on calcium-antagonist monotherapy or untreated patients. Urinary calcium, sodium, and urate correlated positively both in treated and untreated essential hypertension patients. Patients with the higher urinary calcium levels also had higher excretion rates of sodium and urate, higher creatinine clearance rates, and lower serum creatinine and serum uric acid levels. It was concluded that hypercalciuria is a frequent finding of untreated essential hypertension. The association of high urinary calcium levels with high urinary urate excretion rates in the same patient may predispose to development of lithiasis in patients with essential hypertension. Antihypertensive drugs have a variable effect on calciuria-uricosuria, which may constitute an additional criterion in the selection and individualization of therapy. Thiazides and beta-blockers can decrease calciuria and uricosuria and, therefore, the lithogenic risk in these patients.
Quereda
C
C
Nephrology Department, Hospital Ramon y Cajal, Madrid, Spain.
Orte
L
L
Sabater
J
J
Navarro-Antolin
J
J
Villafruela
J J
JJ
Ortuño
J
J
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001581:Benzothiadiazines; D001786:Blood Glucose / Q000032:analysis; D002118:Calcium / Q000652:urine*; D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D003404:Creatinine / Q000097:blood; D004198:Disease Susceptibility; D004232:Diuretics; D004573:Electrolytes / Q000652:urine; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000652:urine*; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000150:complications; D015995:Prevalence; D012083:Renin / Q000097:blood; D049993:Sodium Chloride Symporter Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D014508:Urea / Q000097:blood; D014527:Uric Acid / Q000652:urine; D014545:Urinary Calculi / Q000209:etiology
D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004232:Diuretics; D004573:Electrolytes; D007328:Insulin; D049993:Sodium Chloride Symporter Inhibitors; D014527:Uric Acid; D000450:Aldosterone; D014508:Urea; D003404:Creatinine; D012083:Renin; D002118:Calcium